Casma Therapeutics
3 known investors
Casma Therapeutics develops therapies based on targeted autophagy, using its PHLYT (Phagosome-Lysosome Targeting) platform to initiate target-specific degradation of disease-causing cellular components regardless of size or complexity. The company aims to treat diseases that current drugs have not been able to target.
Investors Β· 3
Frequently asked questions
- What does Casma Therapeutics do?
- Casma Therapeutics develops therapies based on targeted autophagy, using its PHLYT (Phagosome-Lysosome Targeting) platform to initiate target-specific degradation of disease-causing cellular components regardless of size or complexity. The company aims to treat diseases that current drugs have not been able to target.
- Who are Casma Therapeutics's investors?
- Casma Therapeutics's investors include Astellas Venture Management LLC, Eisai Innovation, Inc., Ono Venture Investment, Inc..